SCHEDULE: Millennium Management Discloses 5% Stake in NeoGenomics
Beneficial Ownership Report
Millennium Management LLC, Millennium Group Management LLC, and Israel A. Englander have jointly reported a 5.0% beneficial ownership stake in NeoGenomics, Inc.
Summary
- Millennium Management LLC, Millennium Group Management LLC, and Israel A. Englander have filed a Schedule 13G, indicating their beneficial ownership in NeoGenomics, Inc.
- The reporting persons collectively beneficially own 6,483,428 shares of NeoGenomics, Inc. Common Stock.
- This ownership represents a 5.0% stake in the total class of securities.
- All beneficially owned shares are held with shared voting power and shared dispositive power.
- The acquisition of these securities was not for the purpose of changing or influencing the control of NeoGenomics, Inc.
Sentiment
Score: 6
Explanation: The filing indicates a significant institutional investment by Millennium Management in NeoGenomics, which can be viewed as a vote of confidence, though it is purely a disclosure of ownership and not an operational update.
Positives
- Significant institutional interest from Millennium Management, a prominent investment firm, holding a 5.0% stake in NeoGenomics, Inc., which can be viewed as a vote of confidence.
Future Outlook
No forward-looking statements or guidance are provided in this beneficial ownership report.
Industry Context
This filing indicates a significant investment by a major hedge fund in a company within the diagnostics and oncology sector. Such institutional investments can signal confidence in the company's prospects or the broader sector's growth potential, potentially attracting further investor attention to NeoGenomics and its peers.
Stakeholder Impact
- Shareholders: May view the institutional investment as a positive signal, potentially increasing confidence in the stock.
- Company Management: Awareness of a significant institutional holder may influence strategic decisions or engagement.
Key Dates
| Date | Description |
|---|---|
| 12/02/2025 | Date of event which requires filing of this statement |
| 12/08/2025 | Date of Joint Filing Agreement and Schedule 13G filing |
Keywords
NeoGenomics, Millennium Management, Schedule 13G, beneficial ownership, institutional investment, common stock, NGN
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.